Medicine

Shorter Anti-Viral Treatment for Hepatitis C: Less Effective Than Standard Regimen

Mitchell Shiffman
Mitchell Shiffman

REFERENCE: N Engl J Med 2007;357:124-34
MITCHELL SHIFFMAN, Virginia Commonwealth University, Richmond
Standard anti-viral therapy for Hepatitis C needs to be used to the full duration according to a publication in the New England Journal of Medicine. Following provocative evidence from previous smaller studies, suggesting that anti viral therapy can be shortened, the ACCELERATE trial (the largest international study with genotypes 2 and 3) was set up to resolve whether shortening the duration of therapy for patients would give the same virologic response rates as with the standard regimen. It found that full-dose, full-duration therapy with interferon and ribavirin needs to be adhered to. Nicola Solomon interviewed Mitchell Shiffman to find out more.

Similar Interviews

  • Warfarin Trumps Platelet Agents in Atrial Fibrilation
  • For atrial fibrillation, oral anti-coagulation remains the treatment of choice despite the potential of an anti-platelet regimen based on aspirin

  • Which HIV Treatment is Best for Patients with HIV and Hepatitis C?
  • Juan Berenguer REFERENCE: Abstract V-1385, 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, 2007

  • Entecavir for Hepatitis B Linked to HIV Resistance
  • Moira McMahon REFERENCE:47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, 2007

    Post a comment

    Subscribe to Audio Medica Podcast